Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Understand the replacement chain method, a crucial capital budgeting tool for comparing projects with different life spans. Explore how it works, its requirements, and alternatives.